Nvidia earnings will show another quarter of explosive growth

Nvidia earnings will show another quarter of explosive growth

Equities 4 minutes to read
Peter Garnry

Chief Investment Strategist

Key points

  • Nvidia's strong AI-driven growth: Nvidia is expected to report a significant revenue increase of 113% YoY for FY25 Q2, driven by high demand for its AI chips (Hopper H100 and H200). Analysts anticipate Nvidia will surpass consensus estimates and possibly raise guidance for fiscal Q3, indicating continued strong momentum in the AI industry.

  • Potential political and economic impact of a "Blue Sweep": Although still considered unlikely with a 10% probability, a "Blue sweep" in the upcoming elections could lead to corporate tax hikes, negatively impacting equity markets and valuations. A Harris victory with a split Congress remains the more probable outcome, affecting fiscal stimulus extensions in 2025.

  • Growing momentum for weight-loss drugs: Eli Lilly's Zepbound study shows promising results in preventing diabetes, reinforcing the growing demand for GLP-1 weight-loss drugs. This success could lead to more government and insurance support, further boosting the obesity drug market alongside AI and defense stocks.

Nvidia earnings: The AI growth wave is not ending yet

Nvidia earnings on Wednesday is by far the most important event in global equities. Analysts expect FY25 Q2 (ending 31 July) revenue to hit $28.7bn up 113% YoY and EBITDA of $18.9bn compared to $7.4bn a year ago. Given the underlying momentum in the AI industry and the results we have seen from other companies in the AI ecosystem, we lean in direction of Nvidia beating consensus and lifting guidance for fiscal Q3 surpassing estimates. Demand is still driven by its Hopper chips H100 and H200. Besides revenue guidance the market will anxiously look for an update of its Grace Blackwell 200 chip (GB200) which was scheduled for launch in Q4 2024, but has been postponed to Q1 2025 due to a design flaw. As the chart below shows, the momentum in estimated FY25 Q4 (ending 31 January 2025) revenue is still momentum and has increased from roughly $25bn in the beginning of the year to now $35bn. Our view is that the AI wave will continue until the next GB200 investment has run its course as Google, Meta, and Microsoft will take another bet on compute power to see what it can create in terms of models and new AI applications.

Is the “Blue sweep” scenario suddenly in play?

The “Blue sweep” scenario was unthinkable just one month ago, but with the Harris momentum in polls (see chart) it is no longer a fantasy. It is important to say that this scenario still has a low probability (around 10%). What would it means if we get a “Blue sweep”? Well, it would mean that Harris and the Democratic Party could more easily implement corporate tax hikes from 21% to 28% and just shave off a significant portion of after-tax free cash flows. That would obviously be negative for valuations and equity markets. For now the most likely scenario is a Harris victory with a split Congress which has implications for the macroeconomy in 2025 as it would make extensions of fiscal stimulus much more difficult.

Source: fivethirtyeight.com

Eil Lilly Zepbound study to bolster case for weight lose drugs

Together with AI and European defence stocks the obesity theme has been strong this year as demand is extremely high for the new class of weight-loss drugs Wegovy from Novo Nordisk and Zepbound from Eli Lilly. This week, Eli Lilly announced the results of a three-year long study following patients with the risk of developing diabetes. The study showed that those patients that were on Zepbound compared to the control group had a 94% less likelihood of developing diabetes. This is more evidence that the new GLP-1 weight-loss drugs are preventive as much as curing and thus will likely add support for more government incentives, but also incentivizing insurance companies to increase coverage for these weight-loss drugs.

The week ahead: Nvidia earnings, Germany inflation, and US initial jobless claims

  • Earnings: The key earnings to watch in the week ahead are PDD (Temu, Mon), Nvidia (Wed), and Salesforce (Wed). We have already previewed Nvidia above, so our focus here is on PDD and Salesforce. Analysts expect PDD to report Q2 revenue of CNY 100bn up 91% YoY as its e-commerce platform Temu continues roll over the world with great success connecting the global consumer directly to Chinese factories. PDD is also one of the few Chinese stocks that still have a positive sentiment around it. Salesforce is expected to report FY25 Q2 (ending 31 July) revenue of $9.2bn up 7% YoY as business spending on IT applications is still under pressure from cost focus and attention on AI investments.

  • Germany inflation: Important figures as they are fundamental for the ECB’s thinking on its policy rate path. Estimates are looking for Germany’s August inflation figures to hit 2.1% YoY down from 2.3% YoY in July confirming that inflation has eased and providing flexibility for the ECB to cut its policy rate by 25 basis points (the current market pricing) at the next rate decision meeting on 12 September.

  • US initial jobless claims: Not typically a macro figure we are talking about, but the past two weeks the figure has gotten more attention, because it is a timely indicator on the US labour market. Recent Fed speeches have highlighted US labour market weakness and impacted the market’s pricing of the future Fed funds rate, but the past two weeks, the initial jobless claims have confirmed that the weak July figures were temporary and driven by hurricanes and forced the market to scale back bets on rate hikes. US initial jobless claims are out on Thursday.

Quarterly Outlook

01 /

  • Equity outlook: The high cost of global fragmentation for US portfolios

    Quarterly Outlook

    Equity outlook: The high cost of global fragmentation for US portfolios

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: Commodities rally despite global uncertainty

    Quarterly Outlook

    Commodity Outlook: Commodities rally despite global uncertainty

    Ole Hansen

    Head of Commodity Strategy

  • Upending the global order at blinding speed

    Quarterly Outlook

    Upending the global order at blinding speed

    John J. Hardy

    Global Head of Macro Strategy

    We are witnessing a once-in-a-lifetime shredding of the global order. As the new order takes shape, ...
  • Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Quarterly Outlook

    Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    Quarterly Outlook

    Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    John J. Hardy

    Global Head of Macro Strategy

  • Equity Outlook: The ride just got rougher

    Quarterly Outlook

    Equity Outlook: The ride just got rougher

    Charu Chanana

    Chief Investment Strategist

  • China Outlook: The choice between retaliation or de-escalation

    Quarterly Outlook

    China Outlook: The choice between retaliation or de-escalation

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: A bumpy road ahead calls for diversification

    Quarterly Outlook

    Commodity Outlook: A bumpy road ahead calls for diversification

    Ole Hansen

    Head of Commodity Strategy

  • FX outlook: Tariffs drive USD strength, until...?

    Quarterly Outlook

    FX outlook: Tariffs drive USD strength, until...?

    John J. Hardy

    Global Head of Macro Strategy

  • Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Quarterly Outlook

    Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Althea Spinozzi

    Head of Fixed Income Strategy

None of the information provided on this website constitutes an offer, solicitation, or endorsement to buy or sell any financial instrument, nor is it financial, investment, or trading advice. Saxo Capital Markets UK Ltd. (Saxo) and the Saxo Bank Group provides execution-only services, with all trades and investments based on self-directed decisions. Analysis, research, and educational content is for informational purposes only and should not be considered advice nor a recommendation. Access and use of this website is subject to: (i) the Terms of Use; (ii) the full Disclaimer; (iii) the Risk Warning; and (iv) any other notice or terms applying to Saxo’s news and research.

Saxo’s content may reflect the personal views of the author, which are subject to change without notice. Mentions of specific financial products are for illustrative purposes only and may serve to clarify financial literacy topics. Content classified as investment research is marketing material and does not meet legal requirements for independent research.

Before making any investment decisions, you should assess your own financial situation, needs, and objectives, and consider seeking independent professional advice. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

Please refer to our full disclaimer for more details.

Saxo
40 Bank Street, 26th floor
E14 5DA
London
United Kingdom

Contact Saxo

Select region

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo is a registered Trading Name of Saxo Capital Markets UK Ltd (‘Saxo’). Saxo is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871. Registered in England & Wales.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.

©   since 1992